Blog

Lp(a): The Genetic Cholesterol Risk Factor You Cannot Exercise Away, and the New Drugs Targeting It

Asare B. Christian, MD, MPH · 2026-10-09

Lp(a): The Genetic Cholesterol Risk Factor You Cannot Exercise Away, and the New Drugs Targeting It

The Short Answer

Lipoprotein(a), or Lp(a), is a genetically determined cholesterol particle carried at elevated levels by roughly one in five people, and diet and exercise barely move it. In 2025, gene-silencing injections reduced Lp(a) by more than 90 percent for up to 48 weeks, and a new oral medication improved LDL and apolipoprotein B on top of maximal statin therapy. Measuring Lp(a) once is simple; managing it is finally becoming possible.

What the Evidence Shows

A single injection silenced Lp(a) for nearly a year

The phase 2 trial of lepodisiran, published in the New England Journal of Medicine in 2025, tested an injectable small interfering RNA that silences the gene responsible for Lp(a) production. A single high dose reduced Lp(a) by more than 94 percent for up to 48 weeks, with good tolerability [1]. A companion analysis of the OCEAN(a)-DOSE trial showed that olpasiran, another Lp(a)-lowering siRNA, also reduced oxidized phospholipids, highly inflammatory particles that ride on Lp(a) and drive vascular injury [2].

A new oral option for stubborn LDL

The BROADWAY phase 3 trial evaluated obicetrapib, a once-daily oral CETP inhibitor, in high-risk patients already on maximal statin therapy. It produced significant additional reductions in LDL cholesterol and apolipoprotein B, with a safety profile comparable to placebo [3]. For patients who need more lipid lowering than standard therapy achieves, the toolkit is expanding.

Clinical Interpretation

Lp(a) is the clearest example of cardiovascular risk that is inherited rather than earned. It is measured with a standard blood test, ideally once in every adult's lifetime, and elevated values change the intensity with which every other risk factor should be managed. Until now, the only response to a high Lp(a) was aggressive LDL lowering and lifestyle control. The 2025 data suggest that targeted Lp(a)-lowering is on the horizon, pending outcome trials that prove fewer events, which is the standard that matters.

Limitations and Uncertainties

The lepodisiran and olpasiran results are lipid-lowering and biomarker data, not yet proof of prevented heart attacks; large cardiovascular outcomes trials are ongoing. Obicetrapib's outcome trial is similarly pending. These therapies are not yet available outside trials. Niacin can lower Lp(a) modestly but is not recommended routinely due to side effects.

Who This Applies To

Anyone with a family history of premature heart disease, familial hypercholesterolemia, early stroke or heart attack without conventional risk factors, or progressive atherosclerosis despite good LDL control should know their Lp(a). Because it is genetic, relatives of affected patients often warrant testing too.

How Aether Medicine Approaches Cardiovascular Longevity

Within our ASSESS, RESTORE, OPTIMIZE framework: assessment includes Lp(a), ApoB, lipid particles, inflammation markers, and metabolic health; restoration targets every modifiable driver aggressively, especially when genetics are unfavorable; optimization tracks response objectively over time and coordinates with cardiology when specialty care is indicated.

Frequently Asked Questions

What is Lp(a) exactly?

A cholesterol particle similar to LDL but with an attached protein, apolipoprotein(a), that makes it stickier and more inflammatory. Elevated levels are largely inherited.

How often should Lp(a) be tested?

Generally once in a lifetime, since levels are stable and genetically determined. Rechecking matters mainly with new clinical circumstances or trial eligibility.

Can I lower Lp(a) with diet or exercise?

Not meaningfully. Lifestyle remains essential because it controls everything else, but Lp(a) itself is genetically set. That is precisely why the new targeted therapies matter.

Are these new Lp(a) drugs available now?

Not yet for routine use. Phase 2 and 3 lipid results are very promising, but approval will await cardiovascular outcomes trials.

Where can I get advanced cardiovascular risk testing near Philadelphia?

Aether Medicine is located at 660 American Ave, #103, King of Prussia, PA 19406, serving the Main Line and Greater Philadelphia. Call 484-806-1101 to discuss a consultation.

References

  1. Nissen SE, et al. Lepodisiran: a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2415818
  2. Rosenson RS, et al. Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial. JAMA Cardiol. 2025. https://doi.org/10.1001/jamacardio.2024.5433
  3. Nicholls SJ, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2415820

About the Author

Asare B. Christian, MD, MPH, ABPMR, ABAARM, is Founder and Medical Director of Aether Medicine, double board-certified in Physical Medicine and Rehabilitation and Anti-Aging and Regenerative Medicine, with training at Johns Hopkins and Harvard Medical School. He serves as a Voting Member of the U.S. FDA Pharmacy Compounding Advisory Committee (PCAC), term 2026-2030. This federal advisory role is separate from Aether Medicine's commercial services and does not imply FDA endorsement of the practice or any therapy.

Know Your Numbers, Including the One You Cannot Change

If you want comprehensive cardiovascular risk assessment including Lp(a) and ApoB in King of Prussia, the Main Line, or Greater Philadelphia, call 484-806-1101 or visit https://aethermedicine.com.

Educational information only. This article is a draft for physician review and is not individualized medical advice. Consult your physician before starting, stopping, or changing any treatment.